Liminal Biosciences Profit Margin

As of the most recent data (June 2023), LMNL shows a profit margin of 71.95%. That compares with 9107.96% in the prior-year period — down 99.2% year over year. That is above the Healthcare sector average of 13.89%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LMNL's profit margin is now 71.95% (was 9107.96%) — a 99.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Liminal Biosciences is outperforming or lagging.

The Healthcare sector average profit margin is about 13.89%. Liminal Biosciences is at 71.95%, which is higher that average. That is roughly 418.0% above the sector mean. Use the comparison chart on this page to see how LMNL stacks up against individual peers as well.

That compares with 9107.96% in the prior-year period — down 99.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Liminal Biosciences with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Liminal Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 71.95%) with ownership activity and broader fundamentals.